anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Previous research indicates disparities in the care of bereaved parents and siblings following a stillbirth in the family. The aim of this systematic review was to assess the effects of interventions aimed at reducing psychological distress among parents or siblings in high-income countries after experiencing a stillbirth.
METHODS: The databases CINAHL, Medline, PsycInfo, Cochrane Library, and EMBASE were searched in August 2022.
RESULTS: Four intervention studies from the United States (US), the United Kingdom (UK), Finland, and Australia, met the inclusion criteria. The interventions comprised a perinatal grief support team; a perinatal counselling service; a grief support program; and a support package including contacts with peer supporters and health care staff. No studies of interventions for siblings were found. The results could not be synthesised due to disparities in interventions and outcome measures. The risk of bias was assessed as high in all four studies and the certainty for all outcomes was rated as very low.
CONCLUSION: More controlled trials with rigorous methods are needed to evaluate the effect of bereavement support interventions in parents and siblings after stillbirth. Future studies should include a core outcome set to make them more comparable. Most of the studies in this review were assessed to have an overall high risk of bias, mainly due to problems with missing outcome data; thus, future studies could specifically target this problem.
An image comparison, classification and retrieval system compares objects and object clusters, or images. User controlled or automatic filtering (14) to enhance object features may be performed prior to object definition (16). Calculated parameter set is assigned to defined objects (18). User controlled or automatic object definition system with multi- or single object layer output. The query image may be substantially continuously displayed during the image filtering and object definition processes. The query object, a cluster of objects or an image may be classified as belonging to one of previously defined classes and according to calculated similarity indices. An object, a cluster of objects or an image can be retrieved from an image database based on a query image calculated similarity indices.
Participants will receive monotherapy with placebo matched to lebrikizumab administered via subcutaneous (SC) injection once every 4 weeks up to 52 weeks during the placebo-controlled treatment period. Participants will be allowed to receive treatment with lebrikizumab at a dose of 250 mg administered via SC injection once every 4 weeks up to additional 52 weeks (that is, up to Week 104) in the open-label period.
Disclosed is a vector for nuclear transport of a substance.  Also disclosed is a composition containing the vector. A unilamellar liposome (1a) comprises a lipid membrane (2a) and a substance (3) enclosed in the lipid membrane (2a), wherein a sugar and a peptide comprising contiguous two or more amino acid residues are introduced to the surface of the lipid membrane (2a).  The liposome (1a) can be transported from the outside of a cell to the inside of the cell through the peptide present on the surface of the lipid membrane (2a).  After the liposome (1a) is transported into the cell, the sugar on the surface of the lipid membrane (2a) is bound to a nuclear pore complex.  The sugar bound to the nuclear pore complex is drawn into the nuclear of the cell to cause the disintegration of the lipid membrane (2a), whereby the substance (3) enclosed in the lipid membrane (2a) can be released into the inside of the nuclear through the nuclear pore.
Carbon ion radiotherapy will be administered 5 days each week (Monday-Friday). The prescription dose will be 60 GyE in 20 fractions, to be delivered over four weeks.
Patients should be enrolled if they are receiving 1, 2 or 3 diurnal exchanges of one of the following PD solutions (standard treatment): Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium (1.36%, 2.27% or 3.86% glucose), or Balance, Bicavera, Bicanova or Equibalance (1.5%, 2.3%, 4.25% glucose) - and - one bag of Extraneal (7.5% Icodextrin) for the long-dwell exchange. Patients will be centrally randomized to the investigational product (XyloCore) or the glucose-only PD solution active comparator. Patients randomized to the control group will continue with their prescription of standard treatment with 1, 2 to 3 daily (short-dwell) exchanges of Physioneal, Fixioneal, Dianeal, Balance, Bicavera, Bicanova or Equibalance PD solution. Patients randomized to XyloCore will receive XyloCore Low, Medium or High Strength according to the osmotic strength (glucose concentration) of their prerandomization prescribed PD solution. All patients will keep being prescribed Extraneal (7.5% Icodextrin) for the nocturnal (long-dwell) exchange. The osmotic strength and number of diurnal short dwell exchanges may be modified by the investigator as clinically required. PD prescriptions in both treatment arms should be tailored to reach the minimum target of a total Kt/V of \> 1.7 per week throughout the study. A stratified randomization scheme will be employed to ensure balanced allocation across the two treatment groups of patients with diabetes and of patients treated with only 1 diurnal exchange. Randomization will be performed centrally via a web-based system according to a computer-generated randomization list. The study is open-label with blinded evaluator (primary endpoint), without blinding of patients or clinical staff.
FIELD: medical technology.SUBSTANCE: invention relates to medical technology and reveals a method for applying a bioactive coating to titanium implants. The method for forming a silver-containing biocompatible coating on titanium implants consists in obtaining a coating by preliminary mechanical treatment of the titanium base, surface cleaning, chemical degreasing, an electrospray coating process followed by implantation of silver (Ag+) and copper (Cu+2) ions into it. After degreasing, the polished surface of the titanium base is first treated with an electric spark discharge with the introduction of carbon atoms into the titanium base. The introduction of carbon is carried out at a discharge energy of 0.1-0.35 J and a pulse duration of 60-110 microseconds in an argon medium. Then the treated surface of the titanium base is first treated with a beam of argon cluster ions (Ar+) with the introduction of argon ions into the titanium base and the formation of a porous structure on the surface of the titanium base. At the same time, the introduction of argon cluster ions is carried out with an energy of 30-50 keV, fluence 5⋅1016-2⋅1017cm-2with the direction of the argon ion beam at an angle of 40-60 degrees to the normal to the irradiated surface. Then the formed porous structure is treated with a beam of silver (Ar+) and copper (Cu+2) ions with the introduction of (Ar+) and copper (Cu+2) ions into the formed porous structure of the surface of the titanium base to form an ion-doped layer with antimicrobial properties. At the same time, implantation of silver and copper ions is carried out using an implanter cathode made of Cu-Ag system material with a silver content of 22-45, wt. %, with an energy of 30-50 keV and irradiation fluence (5-9.2) ⋅1017cm-2.EFFECT: increase in the osseointegration properties of intraosseous titanium implants by creating a silver-containing biocompatible coating with antimicrobial properties without a boundary between the coating and the implant surface with a high duration of silver ions entering the biological solution.1 cl, 10 dwg, 3 tbl, 3 ex
FIELD: medicine. SUBSTANCE: method involves temporarily inhibiting intestinal mobility with specially selected dose of ganglioplegic pentamine inducing interruption of pathologic pulse flow in neural parasympathetic ganglia located in intestinal wall. To reduce intensity of intestinal paresis and achieve early restoration and expressed stimulation of peristalsis, pentamine is administered immediately after operation at a dose of 0.6 mg/kg of body mass every 6 h increasing the dose by 0.2 mg/kg every two days. Treatment course duration is 6-7 days. EFFECT: early restoration of intestinal mobility; expressed stimulation of peristalsis. 4 dwg
Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
In addition to the standard enrollment, 6-month, and completion incentives, if the subject loses 5% of their initial weight by the end of the study, they will receive an annual discount (distributed across bi-weekly pay periods) for 12 months beginning after the 12-month study ends. Their premium will return to normal price after this 12-month discount ends.
Cyclooxygenase-2 (COX-2) over-expression is prominent in inflammatory diseases, neurodegenerative disorders, and cancer. Directly monitoring COX-2 activity within its native environment poses an exciting approach to account for and illuminate the effect of the local environments on protein activity. Herein, we report the development of CoxFluor, the first activity-based sensing approach for monitoring COX-2 within live cells with confocal microscopy and flow cytometry. CoxFluor strategically links a natural substrate with a dye precursor to engage both the cyclooxygenase and peroxidase activities of COX-2. This catalyzes the release of resorufin and the natural product, as supported by molecular dynamics and ensemble docking. CoxFluor enabled the detection of oxygen-dependent changes in COX-2 activity that are independent of protein expression within live macrophage cells.
Isradipine is 90% to 95% absorbed and is subject to extensive first-pass metabolism, resulting in a bioavailability of about 15% to 24%. Isradipine is detectable in plasma within 20 minutes after administration of single oral doses of 2.5 to 20 mg, and peak concentrations of approximately 1 ng/mL/mg dosed occur about 1.5 hours after drug administration. Administration of isradipine with food significantly increases the time to peak by about an hour, but has no effect on the total bioavailability (area under the curve) of the drug. Isradipine is 95% bound to plasma proteins. Both peak plasma concentration and AUC exhibit a linear relationship to dose over the 0 to 20 mg dose range. The elimination of isradipine is biphasic with an early half-life of 1 1/2; to 2 hours, and a terminal half-life of about 8 hours. The total body clearance of isradipine is 1.4 L/min and the apparent volume of distribution is 3 L/kg.

Isradipine is completely metabolized prior to excretion, and no unchanged drug is detected in the urine. Six metabolites have been characterized in blood and urine, with the mono acids of the pyridine derivative and a cyclic lactone product accounting for >75% of the material identified. Approximately 60% to 65% of an administered dose is excreted in the urine and 25% to 30% in the feces. Mild renal impairment (creatinine clearance 30 to 80 mL/min) increases the bioavailability (AUC) of isradipine by 45%. Progressive deterioration reverses this trend, and patients with severe renal failure (creatinine clearance <10 mL/min) who have been on hemodialysis show a 20% to 50% lower AUC than healthy volunteers. No pharmacokinetic information is available on drug therapy during hemodialysis. In elderly patients, Cmax and AUC are increased by 13% and 40%, respectively; in patients with hepatic impairment, Cmax and AUC are increased by 32% and 52%, respectively (see DOSAGE AND ADMINISTRATION).
The control group will be treated in the same way as the intervention group, as recommended by the institution's physiotherapist, following its protocols. The same photobiomodulation device will be used as a placebo, but turned off, with a lock on the tip to ensure that no light beam is emitted. The device will be wrapped in PVC plastic film that allows it to be cleaned and changed when used in different patients, avoiding possible contamination. The same irradiation points will be used as in the control group (Figures 2 and 3). The patient may be positioned in bed or on the lap of the person in charge, in the way that is most comfortable for him/her, with the chest bare. The eyes of the patient, the caregiver and the physiotherapist must be properly protected.
Multiple dose (18) HVs: Once Part A has been completed, the data analysed and approved by the DSMB, Part C will be initiated. This part will consist of a repeated-dose cohort based on the higher tolerable dose found in Part A. HVs will be randomized into either the treatment or the placebo arm at a ratio of 2:1 (12 subjects treated with the investigation product and 6 subjects receiving placebo) and will receive the drug/placebo at a daily basis for a total of 10 consecutive days. Each subject will be sampled for PK for 24 hours after first and last dosing and will be daily monitored for drug effects and safety throughout the study period and until 1 week after the last dosing. Real time PK data will be collected and results analysed (as defined in Section 5.2). The PK and safety information gathered from in this part of the study will be evaluated by the DSMB and will guide the dose to be studied in Part D of this study.
New or worsening psychiatric events were reported with SOHONOS use. These include depression, anxiety, mood alterations and suicidal thoughts and behaviors. There is a relatively high background prevalence of psychiatric disorders in untreated patients with FOP. Monitor for development of new or worsening psychiatric symptoms during treatment with SOHONOS [see Adverse Reactions (6.1)]. Individuals with a history of psychiatric illness may be more susceptible to these adverse effects. Patients and/or caregivers should contact their healthcare provider if new or worsening psychiatric symptoms develop during treatment with SOHONOS.
PURPOSE:To provide a detergent compsn. having low irritating properties and improved detergency and hard water resistance by using a particular N-acyl-N- dialkylaminoalkylamino acid (salt). CONSTITUTION:A dialkylaminoalkylamine and a mixture of acrylonitrile, hydroxyacetonitrile and a halogenated acetonitrile are cyanoalkylated at -20 to 70 deg.C to prepare a (dialkylaminoalkylamino)alkylnitrile compd. This compd. is reacted with an acyl chloride at -20 to 70 deg.C in a solvent to prepare an acyl compd. This acyl compd. is hydrolyzed at 60 to 105 deg.C under an alkaline condition, neutralized, dehydrated and desalted, thereby obtaining an N-acyl-N- dialkylaminoalkylamino acid (salt) of the formula (wherein R1 is a 1-21C alkyl or alkenyl; each of R2 and R3 is a 1-6C lower alkyl; m is 1-2; and n is 1-6). The product and, if desired, other surfactants, with the balance being water (C), are mixed together and its pH is adjusted to 4-6. As a result, a detergent is obtd in the form of a liq. or a paste.
Alzheimer's disease (AD) is one of the most devastating international public health epidemics. There are currently no effective disease-modifying or preventative strategies. Current pathogenic models emphasize a single pathway of disease pathogenesis, but underestimate the contribution of small vessel cerebrovascular disease, which manifests primarily as white matter hyperintensities (WMH) on T2-weighted magnetic resonance imaging (MRI). Understanding of the factors that drive the relationship between vascular disease and AD remains elusive; vascular factors may be independent sources of dysfunction that contribute additively to clinical expression, they may interact mechanistically with AD pathology, and/or they may relate to each other because of a shared association with a third set of factors. These issues are particularly relevant among ethnic/racial minorities, who are at much greater risk for clinical AD, have more severe cerebrovascular disease, but appear to have similar levels of AD pathology compared with Whites.

The proposed research examines these factors in a large, longitudinal, multi-ethnic community-based cohort study of older adults in northern Manhattan, New York. The investigators demonstrated that accumulation of WMH, particularly in parietal lobes, predicts incident AD, and is associated with the presence of cerebral microbleeds, an indicator of cerebral amyloid angiopathy. The investigators extend the research to examine mechanistic interactions between cerebrovascular disease and AD. The preliminary data suggest that individuals with evidence of fibrillar amyloidosis have increased parietal lobe WMH and that hemodynamic markers of autoregulatory dysfunction are associated with both WMH and amyloid deposition, which in turn interact to promote the clinical expression of AD. These findings are buffered by new data that establish WMH as a core feature in autosomal dominant forms of AD. In this pilot study, the investigators propose to obtain cross-sectional and longitudinal MRI and amyloid PET data from participants in WHICAP.
This will be a single centre randomized placebo controlled crossover design trial. Participants will be randomized at study entry to protocol A (vitamin E first) or protocol B (placebo first). The first 2 weeks of the study will be a baseline assessment of the frequency, severity and duration of cramps. Patients will be blinded for the remainder of the duration of the study. For weeks 3-6 of the study, group A will receive vitamin E 800 IU bid and group B will receive placebo. For weeks 7-10 of the study, group A will receive placebo and group B will receive vitamin E. Participants will record cramp frequency and characteristics via a daily journal for the duration of the study, however the data analysis will focus on cramp frequency only during weeks 5-6 and 9-10. Weeks 3-4 and 7-8 will be used as time periods to allow the new drug to come to steady state and allow for washout of the previous drug. Data analysis will focus on the difference in cramp frequency in individual patients in each treatment period.
For the non-supervised group, we will propose climbing the stairs from floor 0 to floor 7 three times during the working day and doing planks and stretching exercises outside of work. For the latter, an educational session will be given at the beginning of the study to explain how to perform them correctly.
The treatment program was determined as 3 sessions per week for 8 weeks and 60 minutes per session. The treatment program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.
PROBLEM TO BE SOLVED: To obtain the new physiologically active substance, PF1181 substance, exhibiting a physiological activity similar to that of a nerve growth factor and useful as a medicine for treating diseases caused by nervous disorders, etc., by culturing a physiologically active substance PF1181 substance-producing fungus belonging to the genus Eupenicillium. SOLUTION: A new substance F1181 substance (salt) of the formula. The compound of the formula exhibits a neurite-forming action, has not only physiologically active properties similar to those of a nerve growth factor but also neurotrophic actions such as the survival and function maintenance of nerve cells, and is useful as a therapeutic medicine for diseases caused by various nervous disorders, etc. The new substance PF1181 substance is obtained by culturing a physiologically active substance PF1181 substance-producing fungus belonging to the genus Eupenicillium [e.g. Eupenicillium javanicum var. meloforme PF1181 strain (FERM P-15635)] in a culture medium, and subsequently collecting the product from the culture product.
The database organization and searching systems disclosed herein provide techniques for organizing large-scale image data sources such as medical image databases. Database records such as medical images may be pre-processed, such as through registration, segmentation, and extraction of feature vectors, to effectively normalize data among different images. Each image, or a portion thereof, is then labeled according to some observed characteristic or other attribute. A model, such as a linear regression model, may then be trained to associate the feature vectors with the labels. The model is then available for labeling other images. In this manner, search techniques for well-organized or indexed databases may be applied automatically to databases that are not well-organized, but that have the same underlying data type. Data that is organized in this way may also be used to construct diagnostic aids or other tools.
Bilateral TAP block consisting of 40cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
PanFAM-1 is a prospective, multi-center, investigational study, designed to assess the performance of the IMMray™ PanCan-d test in early detection of pancreatic ductal adenocarcinoma (PDAC) in high-risk populations. Specifically, the IMMray PanCan-d test uses state of the art machine learning algorithms to condense the multiple fluorescence data points generated by the test to a simple yes/no result. Thus, a highly complex statistical model uses the multi-dimensional nature of the test to generate a score, which is called a decision value. The score is compared to the established cut-off value for the test to inform the operator whether the patient sample is positive or negative for PDAC. This study will validate and evaluate the performance of the IMMray PanCan-d test in comparison to standard of care imaging approaches that are currently used in PDAC disease surveillance. Subjects in this study will be recruited from several European and North American research sites that have a PDAC surveillance program or established protocol for monitoring individuals considered to be at a high-risk for developing pancreatic cancer. Any subject that shows disease progression while on-study will be removed from the study to receive standard of care per institutional guidelines. Overall, this study poses minimal risk to subjects. The PanFAM-1 study is an adaptive study design over two approximately 18 month intervals, which are separated by an interim analysis to evaluate diagnostic accuracy of the IMMray PanCan-d test. This study is an observational period in which blood collections from eligible subjects will be evaluated using the IMMray PanCan-d test. Subjects will undergo scheduled imaging assessment and clinical evaluation consistent with the resarch sites' PDAC surveillance program. Subject data derived from the IMMray PanCan-d test during this portion of the study will be delayed from time of initial blood collection until the samples are analyzed. The analysis will compare IMMray PanCan-d test results for each subject to corresponding imaging assessments performed as part of standard of care PDAC surveillance. The study will only proceed to the interventional period if the interim analysis indicates that the diagnostic accuracy of the IMMray PanCan-d test is capable of detecting PDAC in high-risk subjects with the same or better ability as standard of care imaging. If at any time imaging assessments are considered positive for clinical disease then, regardless of IMMray PanCan-d test results, subjects will be managed according to institutional guidelines. All scheduled blood collections for purposes of this study will be halted and subjects will be removed from the study upon confirmation of PDAC.